Sickle Cell Disease Treatment Market: Transforming Patient Care with Cutting-Edge Therapies

The new report published by The Business Research Company, titled Sickle Cell Disease Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the sickle cell disease treatment market size has grown rapidly in recent years. It will grow from $2.46 billion in 2023 to $2.95 billion in 2024 at a compound annual growth rate (CAGR) of 20.0%. The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $5.75 billion in 2028 at a compound annual growth rate (CAGR) of 18.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp

Rising Demand For Blood Transfusions Fuels Growth In The Sickle Cell Disease Treatment Market
The increasing demand for blood transfusions is expected to propel the growth of the sickle cell disease treatment market going forward. A blood transfusion is a medical procedure in which blood or blood products are given from one person (the donor) to another (the receiver). Blood transfusions are a crucial part of treatment for sickle cell disease (SCD) patients because they improve blood's ability to carry oxygen and lessen the difficulties associated with vaso-occlusion. For instance, in December 2022, according to gov.UK, a UK-based public sector information platform, in 2021, the number of blood donations increased, with 1.7 million donations made around the UK. Further, in January 2022, according to Mid-Atlantic Long-Term Care, a US-based provider of specialized 24-hour triage on-call service, in the US, around 29,000 units of red blood cells, 5,000 units of platelets and 6.500 units of plasma are needed every day. Therefore, the increasing demand for blood transfusions is driving the growth of the sickle cell disease treatment market.

Innovative Product Approvals Drive Advancements In Sickle Cell Disease Treatment Market
Major companies operating in the sickle cell disease treatment market are focusing on adopting new product approvals to sustain their position in the market. Drug approval for sickle cell disease treatment is to provide effective treatment options for patients with this lifelong condition. For instance, in December 2021, Global Therapeutics Inc., a US-based biopharmaceutical company, announced the U.S. FDA granted rapid approval for Oxbryta (voxelotor) tablets. These tablets are used to treat sickle cell disease (SCD) in children between the ages of 4 and 11 years. For kids with SCD, Oxbryta is the only FDA-approved medication that specifically prevents sickle hemoglobin polymerization, the underlying cause of sickling and red blood cell destruction in SCD. This is a first-in-class drug that works by increasing the production of fetal hemoglobin (HbF) and it does this by binding to and activating the TNSALP enzyme. This allows the enzyme to break down pyrophosphate, a substance that can interfere with the production of HbF. Oxbryta is administered as a subcutaneous injection once daily.

The sickle cell disease treatment market covered in this report is segmented -

1) By Treatment Modality: Blood Transfusion; Pharmacotherapy; Bone Marrow Transplant
2) By Disease Type: Sickle Cell Anemia; Hemoglobin Sickle C Disease (HbSC); Other Disease Types
3) By Route Of Administration: Oral; Parenteral
4) By End-User: Hospitals; Specialty Clinics; Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13048&type=discount

Major players in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.

Contents of the report:
1. Executive Summary
2. Sickle Cell Disease Treatment Market Report Structure
3. Sickle Cell Disease Treatment Market Trends And Strategies
4. Sickle Cell Disease Treatment Market - Macro Economic Scenario
5. Sickle Cell Disease Treatment Market Size And Growth
…..
27. Sickle Cell Disease Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.